A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Zijing Jia; Kang Wang; Minxiang Xie; Jiajing Wu; Yaling Hu; Yunjiao Zhou; Ayijiang Yisimayi; Wangjun Fu; Lei Wang; Pan Liu; Kaiyue Fan; Ruihong Chen; Lin Wang; Jing Li; Yao Wang; Xiaoqin Ge; Qianqian Zhang; Jianbo Wu; Nan Wang; Wei Wu; Yidan Gao; Jingyun Miao; Yinan Jiang; Lili Qin; Ling Zhu; Weijin Huang; Yanjun Zhang; Huan Zhang; Baisheng Li; Qiang Gao; Xiaoliang Sunney Xie; Youchun Wang; Yunlong Cao; Qiao Wang; Xiangxi Wang

doi:10.1093/procel/pwae033

Protein Cell ›› 2024, Vol. 15 ›› Issue (12) : 930 -937. DOI: 10.1093/procel/pwae033

LETTER

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2

Author information +

¹. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

². Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China

³. Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China

⁴. Sinovac Biotech Ltd., Beijing 100085, China

⁵. Fundamental Research Center, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai 201619, China

⁶. Beijing Advanced Innovation Center for Genomics (ICG), Biomedical Pioneering Innovation Center (BIOPIC), School of Life Science, Peking University, Beijing 100091, China

⁷. Guangzhou Laboratory, Guangzhou 510320, China

⁸. Acrobiosystems Inc., Beijing 102600, China

⁹. Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China

¹⁰. Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China

¹¹. Changping Laboratory, Beijing 102206, China

centrallab5th@163.com

sunneyxie@biopic.pku.edu.cn

wangyc@nifdc.org.cn

yunlongcao@pku.edu.cn

wangqiao@fudan.edu.cn

xiangxi@ibp.ac.cn

Show less

History +

PDF (12285KB)

Cite this article

Download citation ▾

Zijing Jia, Kang Wang, Minxiang Xie, Jiajing Wu, Yaling Hu, Yunjiao Zhou, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu, Kaiyue Fan, Ruihong Chen, Lin Wang, Jing Li, Yao Wang, Xiaoqin Ge, Qianqian Zhang, Jianbo Wu, Nan Wang, Wei Wu, Yidan Gao, Jingyun Miao, Yinan Jiang, Lili Qin, Ling Zhu, Weijin Huang, Yanjun Zhang, Huan Zhang, Baisheng Li, Qiang Gao, Xiaoliang Sunney Xie, Youchun Wang, Yunlong Cao, Qiao Wang, Xiangxi Wang. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. Protein Cell, 2024, 15(12): 930-937 DOI:10.1093/procel/pwae033

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Barnes CO, Jette CA, Abernathy ME et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020a;588:682–687.

[2]	Cao Y, Yisimayi A, Jian F et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022b;608:593–602.

[3]	Chalkias S, Harper C, Vrbicky K et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med 2022;387:1279–1291.

[4]	Fedry J, Hurdiss DL, Wang CY et al. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv 2021;7:eabf5632.

[5]	Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369:77–81.

[6]	Hacisuleyman E, Hale C, Saito Y et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021;384:2212–2218.

[7]	Lv Z, Deng YQ, Ye Q et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 2020;369:1505–1509.

[8]	Muecksch F, Wang Z, Cho A et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 2022;607:128–134.

[9]	Walls AC, Park YJ, Tortorici MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–292.e6 e286.

[10]	Wang Z, Muecksch F, Schaefer-Babajew D et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021f;595:426–431.

[11]	Wang Z, Schmidt F, Weisblum Y et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021g;592:616–622.

[12]	Wang Q, Guo Y, Zhang RM et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis 2023;23:e397–e398.

[13]	Widge AT, Rouphael NG, Jackson LA et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2021;384:80–82.

[14]	Zhao W, Zhao H, Huang B et al. Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination. Signal Transduct Target Ther 2022;7:210.

[15]	Zhou Y, Liu Z, Li S et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep 2021;34:108699.